Treatment with oral mTOR inhibitors was reported by caregivers and patients with TSC, which is likely attributed to the presence of other conditions such as subependymal giant cell astrocytoma, renal angiomyolipoma, pulmonary lymphangioleiomyomatosis, and focal-onset seizures associated with TSC for which use of oral mTOR inhibitors is approved; this use potentially contributes to the improvement of facial angiofibroma [28, 29]. The gene discussed is MTOR; the disease is astrocytoma (excluding glioblastoma).